The SPATA5 gene epilepsy-hearing loss and mental retardation syndrome genetic test is a specialized diagnostic examination aimed at detecting mutations in the SPATA5 gene, which are associated with a rare, genetic disorder. This condition is characterized by a complex spectrum of symptoms, including epilepsy, hearing loss, and varying degrees of intellectual disability. The test involves analyzing the patient's DNA to identify any genetic variations that may indicate the presence of the syndrome, facilitating early diagnosis and intervention.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test is designed for individuals who exhibit symptoms related to the syndrome or have a family history of genetic disorders. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and expertise required to accurately identify the SPATA5 gene mutations. Early detection through this genetic test can be crucial in managing symptoms, tailoring treatments, and improving the quality of life for those affected by this syndrome.
The GABRD gene epilepsy idiopathic generalized type 10 genetic test is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the GABRD gene, which have been linked to epilepsy. Idiopathic generalized epilepsy (IGE) encompasses a group of epilepsy syndromes that do not have a clear cause and are characterized by generalized seizures. The GABRD gene plays a crucial role in encoding a component of the GABA receptor, which is essential for inhibiting neurotransmission in the brain. Mutations in this gene can disrupt normal brain function, leading to the development of epilepsy.
This genetic test is particularly valuable for individuals who have been diagnosed with epilepsy but do not have an identifiable cause for their condition. By pinpointing specific genetic mutations, healthcare providers can gain a better understanding of the nature of the epilepsy, which can inform treatment decisions and potentially lead to more personalized and effective management strategies.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the GABRD gene epilepsy idiopathic generalized type 10 genetic test is 4400 AED. This price reflects the comprehensive nature of the test, including the collection of a DNA sample, usually through a blood draw or cheek swab, the detailed analysis of the GABRD gene, and the provision of a report that interprets the results in the context of the patient's health and family history.
For individuals and families affected by idiopathic generalized epilepsy, this test represents a critical step towards understanding the genetic underpinnings of their condition and can guide more targeted and effective treatment approaches.
The CLCN2 gene epilepsy idiopathic generalized type 11 genetic test is a specialized diagnostic procedure designed to identify mutations in the CLCN2 gene, which have been associated with idiopathic generalized epilepsy type 11 (EIG11). This condition is a form of epilepsy characterized by various seizure types, including absence, myoclonic, and tonic-clonic seizures, without a clear cause. The CLCN2 gene plays a critical role in regulating chloride channels in neurons, and mutations can disrupt normal neuronal activity, leading to seizures.
This genetic test is crucial for individuals with a clinical diagnosis of idiopathic generalized epilepsy, as it can confirm the involvement of the CLCN2 gene mutation. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing it for specific mutations in the CLCN2 gene.
Conducted at DNA Labs UAE, a leading facility in genetic testing and diagnostics, the test offers a comprehensive analysis with reliable results. The cost of the test is set at 4400 AED, reflecting the advanced technology and expertise required to accurately identify the genetic variations associated with this form of epilepsy.
By confirming the genetic basis of the condition, the CLCN2 gene epilepsy idiopathic generalized type 11 genetic test can aid in the personalized management of the disorder, guiding treatment decisions and providing valuable information for family planning.
The SLC2A1 Gene Epilepsy idiopathic generalized type 12 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the SLC2A1 gene, which are associated with Epilepsy, idiopathic generalized type 12. This type of epilepsy is a genetic disorder characterized by seizures with no apparent cause, and it has been linked to variations in the SLC2A1 gene. The test plays a crucial role in the early detection and management of the condition, enabling healthcare providers to tailor treatment plans based on the genetic makeup of the individual.
Priced at 4400 AED, the test is conducted using a sample of the patient's DNA, typically extracted from a blood sample. The process involves advanced genetic sequencing techniques to meticulously analyze the SLC2A1 gene for specific mutations known to contribute to the development of epilepsy. The results from this test can provide valuable insights into the patient's condition, including the likelihood of developing epilepsy, potential response to treatments, and the risk of passing the condition on to future generations.
DNA Labs UAE is known for its state-of-the-art facilities and expertise in genetic testing, offering accurate and reliable results. The test is recommended for individuals with a family history of epilepsy or those who exhibit symptoms associated with the disorder, aiming to provide them with a clearer understanding of their condition and how best to manage it.
The EFHC1 gene plays a crucial role in the development of epilepsy, specifically juvenile absence epilepsy type 1 (JAE1). This condition is characterized by sudden, brief lapses in consciousness, often accompanied by subtle body movements. These episodes, known as absence seizures, typically begin in childhood or adolescence.
The genetic test for identifying mutations in the EFHC1 gene associated with JAE1 is a critical tool for diagnosis and management of the condition. Conducted at DNA Labs UAE, this test involves analyzing the patient's DNA to detect any abnormalities in the EFHC1 gene that may contribute to the development of epilepsy.
Understanding the genetic basis of JAE1 through this test can provide valuable insights into the most effective treatment plans, helping to manage or reduce the frequency of seizures. Additionally, it can offer important information for family planning purposes for those with a family history of epilepsy.
The cost of the EFHC1 gene epilepsy juvenile absence type 1 genetic test at DNA Labs UAE is 4400 AED. This investment in health can be a crucial step towards a more informed and personalized approach to managing juvenile absence epilepsy.
The KCNT1 gene epilepsy nocturnal frontal lobe genetic test is a specialized diagnostic procedure aimed at identifying mutations in the KCNT1 gene, which have been associated with a form of epilepsy that primarily manifests during the night, specifically affecting the frontal lobe of the brain. This condition is known for its challenging nature, as it often resists conventional epilepsy treatments, making the identification of the genetic underpinnings crucial for targeted management and therapeutic strategies.
Conducted at DNA Labs UAE, a facility renowned for its advanced genetic testing capabilities, the test involves collecting a DNA sample from the patient, usually through a blood draw or cheek swab. The sample is then analyzed using state-of-the-art genetic sequencing technologies to detect any abnormalities or mutations in the KCNT1 gene that may be contributing to the epilepsy.
The cost of the KCNT1 gene epilepsy nocturnal frontal lobe genetic test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, encompassing the sophisticated laboratory techniques and expert analysis required to accurately identify mutations in the KCNT1 gene. For patients and families affected by this form of epilepsy, the test offers invaluable insights that can guide more personalized and effective treatment plans, potentially improving quality of life and disease outcomes.
The CHRNA4 Gene Epilepsy Nocturnal Frontal Lobe Type 1 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the CHRNA4 gene, which have been linked to nocturnal frontal lobe epilepsy type 1 (ENFL1). This form of epilepsy is characterized by seizures that predominantly occur during sleep, affecting the frontal lobes of the brain. The CHRNA4 gene plays a crucial role in the regulation of neurotransmitter release in the brain, and mutations in this gene can disrupt normal neurological functions, leading to the development of epilepsy.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, this test is essential for individuals exhibiting symptoms of nocturnal frontal lobe epilepsy or those with a family history of the condition. By analyzing a sample of the patient's DNA, the test can detect specific genetic alterations in the CHRNA4 gene that are responsible for the disorder. This information is invaluable for accurate diagnosis, allowing healthcare providers to tailor treatment plans more effectively and offer genetic counseling to affected families.
The cost of the CHRNA4 Gene Epilepsy Nocturnal Frontal Lobe Type 1 Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the test offers crucial insights into the genetic basis of the condition, enabling better management and understanding of the disease. It represents a critical step towards personalized medicine in the management of epilepsy, providing patients and their families with hope for more targeted and effective treatments.
The CHRNB2 gene is associated with a condition known as Epilepsy, nocturnal frontal lobe type 3 (ENFL3), a disorder characterized by seizures that often occur during sleep. These seizures can manifest as sudden arousals from sleep with motor activity, such as bicycling movements of the legs and hyperkinetic complex movements, often accompanied by vocalizations. This condition is linked to mutations in the CHRNB2 gene, which encodes a subunit of the neuronal nicotinic acetylcholine receptor. These receptors are critical for the proper conduction of signals in the brain, and mutations can disrupt normal neuronal activity, leading to seizures.
Genetic testing for mutations in the CHRNB2 gene can be crucial for the diagnosis and management of ENFL3. By identifying specific genetic alterations, healthcare providers can offer more personalized treatment plans and advice on managing the condition. Moreover, genetic testing can help to confirm a diagnosis when the clinical presentation is unclear and can also provide valuable information for family planning.
In the United Arab Emirates, DNA Labs UAE offers a genetic test specifically targeting the CHRNB2 gene to identify mutations associated with Epilepsy, nocturnal frontal lobe type 3. The cost of the test is 4400 AED. This specialized test is performed in a state-of-the-art laboratory setting by experienced professionals, ensuring high-quality, reliable results. By opting for this test, individuals and families affected by or at risk of ENFL3 can gain crucial insights into their condition, paving the way for informed decisions about treatment and management.
The MT-TL2 gene encodes for mitochondrial tRNA for leucine (UUA/G), and mutations in this gene can lead to mitochondrial encephalomyopathy, a condition characterized by brain and muscle dysfunction due to issues in mitochondrial energy production. The MT-TL2-related genetic test is a specialized diagnostic tool designed to identify mutations in the MT-TL2 gene, which can help in diagnosing mitochondrial encephalomyopathy linked to this gene. This test is crucial for confirming the diagnosis, understanding the disease progression, and informing treatment strategies for affected individuals.
The test is available at DNA Labs UAE, a leading facility in genetic testing and analysis. The cost of the MT-TL2 gene encephalomyopathy-related genetic test is 4400 AED. Conducted in a state-of-the-art laboratory by experienced professionals, this test offers a reliable diagnosis for patients suspected of having mitochondrial disorders associated with the MT-TL2 gene. Early detection through this test can be instrumental in managing symptoms and improving the quality of life for those affected by mitochondrial encephalomyopathy.
The MT-TR gene encephalomyopathy mitochondrial MT-TR related genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the MT-TR gene that are associated with mitochondrial encephalomyopathy. This condition is a complex mitochondrial disorder characterized by neurological and muscular impairments, resulting from dysfunctional energy production in the mitochondria. The MT-TR gene plays a crucial role in the mitochondrial function, and mutations in this gene can lead to a range of symptoms, including muscle weakness, neurological deficits, and systemic energy metabolism issues.
The test involves analyzing the patient's DNA to detect mutations in the MT-TR gene, providing valuable information for diagnosis, prognosis, and treatment planning. It is a critical tool for clinicians in the management of patients with suspected mitochondrial disorders, offering insights that can guide personalized treatment approaches.
DNA Labs UAE offers this comprehensive genetic test for a cost of 4400 AED. The test is conducted in their state-of-the-art laboratory facilities, where they utilize advanced genetic sequencing technologies to ensure accurate and reliable results. Patients considering this test are usually referred by their healthcare provider based on clinical symptoms and family history suggestive of mitochondrial encephalomyopathy. The results from this test can significantly impact patient care, offering a clearer understanding of the disease mechanism and potential therapeutic interventions.
